Log In
BCIQ
Print this Print this
 

Pancragen (PathFinder TG molecular diagnostic assay for pancreatic cancer)

  Manage Alerts
Collapse Summary General Information
Company Interpace Diagnostics Group Inc.
DescriptionAssay that uses loss of heterozygosity (LOH) markers, oncogene mutations and DNA content abnormalities to stratify patients according to their risk of progression to cancer
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose risk of pancreatic cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$32.0M

$24.5M

$9.5M


 Deals Details
Get a free BioCentury trial today